Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|June 13, 2025
Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trialH Blons, J Abdelli, S Landman, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|March 6, 2026
Radiomics-based ultrasOund Model for differentiating Uterine Sarcomas from leiomyomas (ROMUS): a retrospective pilot Multicenter Italian Trials in Ovarian Cancer (MITO) studyF Ciccarone, A Rizzi, A Biscione, et al.
Gynecologic Oncology|September 28, 2020
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trialMansoor R Mirza, B Benigno, A Dørum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent diseaseM K Wilson, E Pujade-Lauraine, D Aoki, et al.
ESMO Open|April 2, 2025
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studyC Marchetti, A Fagotti, R Fruscio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancerM C Piccirillo, G Scambia, A Bologna, et al.
ESMO Open|May 20, 2025
HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparibL Beltrame, L Mannarino, A Sergi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2024
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapyS Pignata, D Califano, D Lorusso, et al.
ESMO Open|September 26, 2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trialE D Capoluongo, B Pellegrino, L Arenare, et al.
ESMO Open|January 25, 2023
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancerS Koppikar, A Oaknin, K Govind Babu, et al.
Pageof 15